Colin Love Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 4 days, 6 hours ago
Colin Love has an estimated net worth of at least $10.8 million*, as of May 7, 2025. They own 777,345 shares of REPL stock. They have sold 184,714 shares of REPL stock since 2021, for an estimated $5.1 million.
Colin Love $REPL SEC Form 4 Insider Trading
Colin Love has filed a total of 12 insider trades in $REPL since 2021. Their most recent trade was a sale of 17,615 shares, made on May 16, 2024. Their largest trade was a sale of 30,000 shares, made on Sep 15, 2021. We estimate that they now own 777,345 shares of $REPL, worth an estimated $5.7 million.
Insider Trading at $REPL
There have been a total of 80 insider trades reported at $REPL since 2021, with 0 shares purchased and 965,602 shares sold. The most active insider traders in $REPL stock have been Pamela Esposito, Colin Love, and Konstantinos Xynos. The most recent trade was a sale of 10,000 shares reported by Sushil Patel (Chief Executive Officer), made on Dec 16, 2024.
History of Insider Stock Trades by Colin Love
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
![]() |
Sale | 17,615 | May 16, 2024 | May 20, 2024, 8:05 p.m. |
![]() |
Sale | 10,775 | May 16, 2023 | May 18, 2023, 8:33 p.m. |
![]() |
Sale | 6,324 | May 16, 2022 | May 18, 2022, 7:04 p.m. |
![]() |
Sale | 2,200 | Oct 15, 2021 | Oct. 18, 2021, 8 p.m. |
![]() |
Sale | 15,089 | Oct 15, 2021 | Oct. 18, 2021, 8 p.m. |
![]() |
Sale | 12,711 | Oct 18, 2021 | Oct. 18, 2021, 8 p.m. |
![]() |
Sale | 30,000 | Sep 15, 2021 | Sept. 16, 2021, 8 p.m. |
![]() |
Sale | 27,300 | Aug 16, 2021 | Aug. 17, 2021, 8 p.m. |
![]() |
Sale | 2,700 | Aug 16, 2021 | Aug. 17, 2021, 8 p.m. |
![]() |
Sale | 30,000 | Jul 15, 2021 | July 15, 2021, 8 p.m. |
![]() |
Sale | 17,800 | Jun 15, 2021 | June 15, 2021, 8 p.m. |
![]() |
Sale | 12,200 | Jun 15, 2021 | June 15, 2021, 8 p.m. |
$REPL Executives and Stock Owners with Insider Trades
-
Pamela Esposito, Chief Business Officer
-
Colin Love, Chief Operating Officer
-
Konstantinos Xynos, Chief Medical Officer
-
Robert Coffin, President & Chief R&D Officer
-
Christopher Sarchi, Chief Commercial Officer
-
Sushil Patel, Chief Strategy Officer
-
Tanya Lewis, Chief Dev. Op. Officer
-
Jean M. Franchi, Chief Financial Officer
-
Philip Astley-Sparke, Chief Executive Officer
-
Sushil Patel, Chief Executive Officer
-
Andrew Schwendenman, Chief Accounting Officer
-
Emily Luisa Hill, Chief Financial Officer
-
Philip Astley-Sparke, Executive Chairman
-
Sushil Patel, Chief Commercial Officer
-
Tanya Lewis, Chief Dev. Op Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.